Filing Details
- Accession Number:
- 0001209191-21-055954
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-14 17:00:54
- Reporting Period:
- 2021-09-13
- Accepted Time:
- 2021-09-14 17:00:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
850261 | Sorrento Therapeutics Inc. | SRNE | Biological Products, (No Disgnostic Substances) (2836) | 330344842 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1518466 | Kim Janda | C/O Sorrento Therapeutics, Inc. 4955 Directors Place San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-09-13 | 8,000 | $3.50 | 11,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-09-13 | 8,000 | $8.04 | 3,000 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-qualified stock option | Disposition | 2021-09-13 | 8,000 | $0.00 | 8,000 | $3.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2021-09-28 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.84 to $8.23, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
- 25% of the shares subject to the option vested on September 28, 2012, and 1/48th of the shares subject to the option vested monthly thereafter.